Royalty Pharma PLC

Royalty Pharma PLC (NASDAQ: RPRX) is a buyer of biopharmaceutical royalties, and the portfolio consists of royalties on around 45 therapies.

RPRX will pay a quarterly dividend of USD 0.17 with respect to Q3 FY21 on 15 September 2021, with an ex-dividend date of 19 August 2021

Investment Highlights – Buy at USD 39.09

• Post releasing Q2 FY21 results, RPRX had increased the full-year 2021 guidance for adjusted cash receipts ranging from USD 2.08 billion to USD 2.12 billion. Earlier, it was expected to fall between USD 1.94 billion and USD 1.98 billion.
• The key performance indicators like adjusted cash receipts & adjusted EBITDA had shown a modest growth during Q2 FY21 as compared to Q2 FY20.
• On the liquidity front, RPRX has a current ratio of 9.53x, higher than the industry median of 2.73x during Q2 FY21.
• From a technical standpoint, the MACD line remained above the signal line, indicating an upside potential in the stock price.
• Moreover, the 20-days exponential moving average price of USD 38.43 is supporting the upside potential in the stock price.

Key Risks

• The failure to adapt to changing consumer needs could impact sales and profit.
• The Company has a significantly higher debt when compared with the industry.
• The increased number of Covid-19 cases in the US might hamper the growth prospects of RPRX.

Q2 FY21 Financial Highlights for the three months period ended 30 June 2021 (as of 11 August 2021)

 (Source: Company Result)

• The adjusted cash receipts had shown a marginal increase of about 3% during Q2 FY21.
• Driven by the recently acquired assets, the total income & other revenues had shown a decent growth of around 9% to USD 555 million during Q2 FY21.
• RPRX had cash & cash equivalents of around USD 2.00 billion as of 30 June 2021.

One Year Share Price Chart

 (Source: Refinitiv; Analysis done by Kalkine Group)

Valuation Methodology: Price/Earnings Approach (NTM) (Illustrative)

Conclusion

The Company had strengthened the business model to gain significant market share in the rapidly growing biopharma royalty funding market with announced acquisitions worth USD 4.7 billion. Moreover, the Company expects payments for operating & professional costs to remain around 9% to 10% of adjusted cash receipts in 2021. Meanwhile, the Company had exhibited its funding capabilities as it entered a strategic funding partnership with MorphoSys. The stock made a 52-week High and Low of USD 53.23 and USD 34.80, respectively.

Considering the improved guidance, consistent dividend payments, and valuation conducted above, we have given a "BUY" stance on Royalty Pharma PLC at the closing market price of USD 39.09 (as on 17 August 2021) with a lower-double digit upside potential based on 17.49x Price/NTM Earnings (approx.) on FY21E earnings per share (approx.).

*The reference data in this report has been partly sourced from REFINITIV.

*All forecasted figures and Peer information have been taken from REFINITIV.

*Dividend Yield may vary as per the stock price movement.

*Depending upon the risk tolerance, investors may consider unwinding their positions in a respective stock once the estimated target price is reached.

Disclaimer

References to ‘Kalkine’, ‘we’, ‘our’ and ‘us’ refer to Kalkine Limited.

This website is a service of Kalkine Limited. Kalkine Limited is a private limited company, incorporated in England and Wales with registration number 07903332. Kalkine Limited is authorised and regulated by the Financial Conduct Authority under reference number 579414.

The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. No advice or information, whether oral or written, obtained by you from Kalkine or through or from the service shall create any warranty not expressly stated. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation.

Kalkine does not offer financial advice based upon your personal financial situation or goals, and we shall NOT be held liable for any investment or trading losses you may incur by using the opinions expressed in our publications, market updates, news alerts and corporate profiles. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation. Kalkine’s non-personalised advice does not in any way endorse or recommend individuals, investment products or services for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional authorised financial planner and adviser. You should be aware that the value of any investment and the income from it can go down as well as up and you may not get back the amount invested.